USPSTF Finds Evidence Lacking for Sleep Apnea Screening

Share this content:
USPSTF Finds Evidence Lacking for Sleep Apnea Screening
USPSTF Finds Evidence Lacking for Sleep Apnea Screening

TUESDAY, June 14, 2016 (HealthDay News) -- The U.S. Preventive Services Task Force (USPSTF) has found insufficient evidence for the benefit of obstructive sleep apnea (OSA) screening in asymptomatic populations. These findings form the basis of a draft recommendation statement, published online June 14 by the USPSTF.

Daniel E. Jonas, M.D., M.P.H., from the RTI International-University of North Carolina at Chapel Hill in Research Triangle Park, and colleagues conducted a systematic review of the evidence for screening and treating asymptomatic adults or those with unrecognized symptoms for OSA. Data were included from 110 studies.

The researchers found that none of the randomized controlled trials compared screening with no screening. There was inadequate direct evidence on the benefit of screening in asymptomatic populations. No studies assessed the effect of screening on health outcomes. Based on these findings, the USPSTF concluded that the evidence is currently insufficient to weigh the balance of benefits and harms of OSA screening in asymptomatic adults (I statement). The draft recommendation statement has been posted for public comment from June 14 to July 11, 2016.

"The Task Force is calling for more research on whether screening in adults without known symptoms leads to improvements in health outcomes such as heart attacks, strokes, quality of life, and mortality," Task Force member Alex H. Krist, M.D., M.P.H., said in a statement.

Evidence Review
Draft Recommendation Statement
Comment on Recommendations

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »